Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer

中止 医学 内科学 不利影响 肺癌 进行性疾病 胃肠病学 毒性 疾病
作者
Federica Pecci,Rohit Thummalapalli,Stephanie Alden,Biagio Ricciuti,Joao V. Alessi,Arielle Elkrief,Hira Rizvi,Xinan Wang,Mark Jeng,Jacklynn V. Egger,Victor R. Vaz,Adriana Barrichello,Giuseppe Lamberti,Alessandro Di Federico,Valentina Santo,Guilherme Rossato de Almeida,Malini Gandhi,Phoebe Clark,Mizuki Nishino,Bruce E. Johnson
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:31 (12): 2413-2425 被引量:8
标识
DOI:10.1158/1078-0432.ccr-24-2990
摘要

PURPOSE: Among patients with advanced non-small cell lung cancer (NSCLC) who discontinue immune checkpoint inhibitors (ICI) because of immune-related adverse events (irAE), post-discontinuation clinical outcomes and factors associated with disease progression after discontinuation are largely unknown. EXPERIMENTAL DESIGN: Clinicopathologic data were abstracted from patients with advanced NSCLC who received ICI and discontinued treatment because of irAE. Factors associated with post-discontinuation progression-free survival (PFS) and post-discontinuation overall survival (OS) were evaluated. RESULTS: Of 2,794 patients, 10% (N = 271) discontinued ICI because of irAE, and the median duration of ICI treatment before discontinuation for irAE was 5.9 months (range, 0.03-73.5). A longer treatment duration before discontinuation for irAE was associated with improved post-discontinuation outcomes: for patients on ICI for <3 months (N = 89), 3 to 6 months (N = 49), and >6 months (N = 133) before discontinuing for irAE, the median post-discontinuation PFS was 6.2, 13.9, and 25.8 months (P < 0.001), respectively, and the median post-discontinuation OS was 21.7, 42.7, and 86.9 months (P < 0.001), respectively. At multivariable analyses, predictors of longer post-discontinuation PFS were PD-L1 ≥ 50%, complete response/partial response (CR/PR) to treatment, and treatment duration before discontinuation between 3 to 6 months and >6 months; predictors of longer post-discontinuation OS were nonsquamous histology, CR/PR, and treatment duration before discontinuation >6 months. The use of immunosuppressive agents for toxicity management did not affect post-discontinuation outcomes. CONCLUSIONS: A longer treatment duration before discontinuation, a best objective response of CR/PR, PD-L1 ≥50%, and nonsquamous histology may help clinicians identify patients who may experience long-term disease control after discontinuation of ICI for irAE.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
旋同完成签到,获得积分10
1秒前
1秒前
1秒前
2秒前
njfu发布了新的文献求助10
2秒前
奔赴完成签到 ,获得积分10
2秒前
Genger完成签到,获得积分10
2秒前
病毒遗传学完成签到,获得积分10
2秒前
2秒前
lzm完成签到,获得积分10
2秒前
乐乐的应助被huhuiya采纳,获得10
2秒前
草莓派完成签到,获得积分10
2秒前
lyt发布了新的文献求助10
2秒前
Subwaid的应助被科研通管家采纳,获得10
3秒前
英俊的铭的应助被科研通管家采纳,获得10
3秒前
高贵振家完成签到,获得积分10
3秒前
大模型的应助被科研通管家采纳,获得10
3秒前
烟花的应助被科研通管家采纳,获得10
3秒前
3秒前
脑洞疼的应助被科研通管家采纳,获得10
3秒前
丘比特的应助被科研通管家采纳,获得10
3秒前
珍珠完成签到,获得积分10
3秒前
3秒前
脑洞疼的应助被科研通管家采纳,获得10
3秒前
科研通AI65的应助被萌萌大头菜采纳,获得10
3秒前
图图耳朵的应助被科研通管家采纳,获得30
3秒前
打打的应助被科研通管家采纳,获得10
4秒前
搜集达人的应助被科研通管家采纳,获得10
4秒前
霸气的初阳完成签到,获得积分10
4秒前
英俊的铭的应助被科研通管家采纳,获得10
4秒前
lzm发布了新的文献求助10
4秒前
Akim的应助被科研通管家采纳,获得10
4秒前
6666的应助被科研通管家采纳,获得10
4秒前
天天快乐的应助被科研通管家采纳,获得10
4秒前
空城完成签到,获得积分10
4秒前
Martin的应助被科研通管家采纳,获得20
4秒前
田様的应助被科研通管家采纳,获得10
5秒前
Lucas的应助被科研通管家采纳,获得10
5秒前
5秒前
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287